1. Home
  2. NVCR vs DSL Comparison

NVCR vs DSL Comparison

Compare NVCR & DSL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NVCR
  • DSL
  • Stock Information
  • Founded
  • NVCR 2000
  • DSL 2013
  • Country
  • NVCR Switzerland
  • DSL United States
  • Employees
  • NVCR N/A
  • DSL N/A
  • Industry
  • NVCR Medical/Dental Instruments
  • DSL Trusts Except Educational Religious and Charitable
  • Sector
  • NVCR Health Care
  • DSL Finance
  • Exchange
  • NVCR Nasdaq
  • DSL Nasdaq
  • Market Cap
  • NVCR 1.3B
  • DSL 1.4B
  • IPO Year
  • NVCR 2015
  • DSL N/A
  • Fundamental
  • Price
  • NVCR $11.25
  • DSL $11.44
  • Analyst Decision
  • NVCR Buy
  • DSL
  • Analyst Count
  • NVCR 7
  • DSL 0
  • Target Price
  • NVCR $28.64
  • DSL N/A
  • AVG Volume (30 Days)
  • NVCR 1.5M
  • DSL 673.5K
  • Earning Date
  • NVCR 10-30-2025
  • DSL 01-01-0001
  • Dividend Yield
  • NVCR N/A
  • DSL 10.60%
  • EPS Growth
  • NVCR N/A
  • DSL N/A
  • EPS
  • NVCR N/A
  • DSL N/A
  • Revenue
  • NVCR $642,269,000.00
  • DSL N/A
  • Revenue This Year
  • NVCR $9.54
  • DSL N/A
  • Revenue Next Year
  • NVCR $5.70
  • DSL N/A
  • P/E Ratio
  • NVCR N/A
  • DSL N/A
  • Revenue Growth
  • NVCR 11.17
  • DSL N/A
  • 52 Week Low
  • NVCR $10.70
  • DSL $10.58
  • 52 Week High
  • NVCR $34.13
  • DSL $13.00
  • Technical
  • Relative Strength Index (RSI)
  • NVCR 35.05
  • DSL 29.27
  • Support Level
  • NVCR $10.70
  • DSL $11.50
  • Resistance Level
  • NVCR $12.01
  • DSL $11.63
  • Average True Range (ATR)
  • NVCR 0.57
  • DSL 0.11
  • MACD
  • NVCR -0.11
  • DSL 0.00
  • Stochastic Oscillator
  • NVCR 15.48
  • DSL 4.00

About NVCR NovoCure Limited

NovoCure Ltd is an oncology company with a propreitary platform technology in United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.

About DSL DoubleLine Income Solutions Fund of Beneficial Interests

DoubleLine Income Solutions Fund is a closed-end management investment company. Its primary investment objective is to seek high income and its secondary objective is to seek capital appreciation. It invests in debt securities and other income-producing investments anywhere in the world, including emerging markets. The company's investment portfolio comprises foreign corporate bonds, U.S. corporate bonds, bank loans, collateralized loan obligations, non-agency commercial mortgage backed obligations, asset-backed obligations, and municipal bonds among others.

Share on Social Networks: